Literature DB >> 34233940

Clinical Efficacy, Drug Safety, and Surrogate Endpoints: Has Aducanumab Met All of Its Expectations?

Linda A Hershey1, Rawan Tarawneh2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34233940     DOI: 10.1212/WNL.0000000000012453

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   11.800


× No keyword cloud information.
  4 in total

1.  Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.

Authors:  Andreea L Turcu; Júlia Companys-Alemany; Matthew B Phillips; Dhilon S Patel; Christian Griñán-Ferré; M Isabel Loza; José M Brea; Belén Pérez; David Soto; Francesc X Sureda; Maria G Kurnikova; Jon W Johnson; Mercè Pallàs; Santiago Vázquez
Journal:  Eur J Med Chem       Date:  2022-04-08       Impact factor: 7.088

2.  Expedited regulatory product approval in the time of COVID-19.

Authors:  Gary D Novack
Journal:  Ocul Surf       Date:  2022-05-28       Impact factor: 6.268

Review 3.  Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?

Authors:  Serena Silvestro; Andrea Valeri; Emanuela Mazzon
Journal:  Int J Mol Sci       Date:  2022-02-11       Impact factor: 5.923

4.  Practical Considerations in the Administration of Aducanumab for the Neurologist.

Authors:  Katherine Coerver; Melissa M Yu; Anelyssa D'Abreu; Marc Wasserman; Kavita V Nair
Journal:  Neurol Clin Pract       Date:  2022-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.